This work aimed to explore the accuracy of magnetic resonance imaging (MRI) images based on the convolutional neural network (CNN) algorithm in the diagnosis of prostate cancer patients and tumor risk grading. A total of 89 patients with prostate cancer and benign prostatic hyperplasia diagnosed by MRI examination and pathological examination in hospital were selected as the research objects in this study (they passed the exclusion criteria). The MRI images of these patients were collected in two groups and divided into two groups before and after treatment according to whether the CNN algorithm was used to process them. The number of diagnosed diseases and the number of cases of risk level inferred based on the tumor grading were compared to observe which group was closer to the diagnosis of pathological biopsy. Through comparative analysis, compared with the positive rate of pathological diagnosis (44%), the positive rate after the treatment of the CNN algorithm (42%) was more similar to that before the treatment (34%), and the comparison was statistically marked ( < 0.05). In terms of risk stratification, the grading results after treatment (37 cases) were closer to the results of pathological grading (39 cases) than those before treatment (30 cases), and the comparison was statistically obvious ( < 0.05). In addition, it was obvious that the MRT images would be clearer after treatment through the observation of the MRT images before and after treatment. In conclusion, MRI image segmentation algorithm based on CNN was more accurate in the diagnosis and risk stratification of prostate cancer than routine MRI. According to the evaluation of Dice similarity coefficient (DSC) and Hausdorff I distance (HD), the CNN segmentation method used in this study was more perfect than other segmentation methods.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643240 | PMC |
http://dx.doi.org/10.1155/2021/1034661 | DOI Listing |
Ann Intern Med
January 2025
Durham VA Health Care System, Durham; and Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (K.M.G.).
Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.
Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.
Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.
Ann Intern Med
January 2025
Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
Oncologist
January 2025
Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.
Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2) and cluster of differentiation 3, in mCRPC.
Patients And Methods: Patients who had measurable/evaluable mCRPC after at least one novel androgen receptor-targeted therapy or chemotherapy were eligible.
Mol Biotechnol
January 2025
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Opioids are the primary regimens for perioperative analgesia with controversial effects on oncological survival. The underlying mechanism remains unexplored. This study developed survival-related gene co-expression networks based on RNA-seq and clinical characteristics from TCGA cohort.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!